13.4 Anxiolytics and Sedative-Hypnotics

Anxiolytics and Sedative-Hypnotics

Anxiolytics and sedative-hypnotics are medications used to manage anxiety disorders and sleep disturbances. They primarily work by enhancing GABA activity or targeting specific receptors in the brain to reduce anxiety and promote sleep. Nurses need a solid grasp of how these drugs work, their side effect profiles, and the key safety concerns that come with administering them.

Features of Anxiolytics and Sedative-Hypnotics

Anxiolytics reduce symptoms of anxiety disorders such as generalized anxiety disorder (GAD), panic disorder, and phobias. They target restlessness, nervousness, and excessive worry.

• Benzodiazepines (alprazolam, lorazepam) are fast-acting and commonly used for acute anxiety
• Buspirone is a non-benzodiazepine anxiolytic used for chronic anxiety; it takes 2–4 weeks to reach full therapeutic effect, so it's not useful for acute episodes

Sedative-hypnotics treat insomnia and other sleep disorders by promoting sleep onset, maintaining sleep duration, or both.

• Benzodiazepine hypnotics (temazepam, triazolam) promote sleep but carry dependence risk
• Non-benzodiazepine hypnotics, often called "Z-drugs" (zolpidem, eszopiclone), are more selective for sleep induction with less anxiolytic or muscle relaxant activity
• Melatonin receptor agonists (ramelteon) regulate the sleep-wake cycle and have the lowest abuse potential in this category

Mechanisms and Effects of Anxiety and Sleep Medications

Each drug class works through a different mechanism, which directly shapes its side effect profile and drug interaction risks.

Benzodiazepines enhance the activity of GABA, the primary inhibitory neurotransmitter in the CNS. They bind to the GABA-A receptor and increase the frequency of chloride channel opening, which depresses CNS activity broadly.

• Side effects: drowsiness, dizziness, impaired coordination, memory impairment, respiratory depression
• Additive CNS depression occurs with alcohol, opioids, and other CNS depressants
• Increased risk of falls and fractures in older adults
• Carry significant dependence and withdrawal risk with prolonged use

Buspirone acts as a partial agonist at serotonin 5-HT1A receptors. It reduces anxiety without causing significant sedation, cognitive impairment, or dependence.

• Side effects: dizziness, nausea, headache, nervousness
• Combining with other serotonergic agents (SSRIs, SNRIs, MAOIs) may increase the risk of serotonin syndrome
• No abuse potential and no cross-tolerance with benzodiazepines

Non-benzodiazepine hypnotics (Z-drugs) bind selectively to the alpha-1 subunit of the GABA-A receptor. This selectivity promotes sleep without producing the broad anxiolytic, anticonvulsant, or muscle relaxant effects seen with benzodiazepines.

• Side effects: drowsiness, dizziness, headache, and complex sleep behaviors (sleepwalking, sleep-driving, sleep-eating)
• Additive CNS depression with alcohol and other depressants
• The FDA requires a boxed warning about complex sleep behaviors for this class

Melatonin receptor agonists (ramelteon) bind to MT1 and MT2 receptors in the suprachiasmatic nucleus, which is the brain's master clock for circadian rhythm. This helps regulate the sleep-wake cycle naturally.

• Side effects: dizziness, fatigue, headache
• Minimal drug interactions because ramelteon has limited cytochrome P450 involvement (though fluvoxamine is a notable exception and is contraindicated)
• No abuse potential and not a controlled substance

Pharmacokinetics and Tolerance

Half-life varies widely across this drug class and directly affects how you use them clinically:

• Short-acting agents (triazolam, zolpidem) are better for sleep onset but wear off quickly
• Long-acting agents (diazepam, with active metabolites lasting 20–100 hours) provide sustained effect but increase next-day sedation risk, especially in older adults

Metabolism occurs primarily in the liver. Some benzodiazepines (like diazepam) produce active metabolites that extend their duration of action. Lorazepam, oxazepam, and temazepam ("LOT" drugs) undergo glucuronidation rather than oxidative metabolism, making them safer choices for patients with hepatic impairment or older adults.

Tolerance may develop with prolonged use, meaning higher doses are needed for the same effect. This is especially true for benzodiazepines. Cross-tolerance can occur between drugs with similar mechanisms. For example, a patient who drinks alcohol heavily may need higher benzodiazepine doses because both act on GABA receptors.

Nursing Considerations for Sedatives

Assessment before administration:

1. Review the patient's medical history, current medications, allergies, and comorbidities (especially hepatic or respiratory disease)
2. Assess baseline anxiety level or sleep quality using validated tools such as the GAD-7 for anxiety or the Insomnia Severity Index for sleep
3. Evaluate for risk factors: older age, history of substance use, respiratory compromise, concurrent CNS depressant use

Administration and monitoring:

1. Administer at the correct dose, route, and timing (sedative-hypnotics should be given immediately before bedtime, not hours earlier)
2. Monitor vital signs, level of consciousness, and respiratory status, particularly with benzodiazepines or when other CNS depressants are on board
3. Watch for signs of oversedation, respiratory depression, or complex sleep behaviors
4. Be alert for paradoxical reactions (agitation, aggression, confusion), which are more common in elderly patients and children

Safety interventions:

• Implement fall prevention strategies: bed alarm, call light within reach, non-skid footwear, assisted ambulation
• Ensure the flumazenil reversal agent is available when administering IV benzodiazepines (flumazenil competitively blocks the benzodiazepine binding site on the GABA-A receptor)
• Educate patients not to operate heavy machinery or drive while taking these medications

Patient Education for Sleep and Anxiety Medications

Medication use:

• Explain the purpose, expected benefits, and potential side effects of the prescribed medication
• Stress the importance of taking the medication exactly as directed and not adjusting the dose independently
• For buspirone specifically, set the expectation that therapeutic effects take 2–4 weeks to appear

Avoiding dangerous combinations:

• Advise patients to avoid alcohol and other CNS depressants while taking anxiolytics or sedative-hypnotics
• Specifically warn about the respiratory depression risk when combining benzodiazepines with opioids

Non-pharmacological strategies:

• Encourage sleep hygiene practices: consistent sleep schedule, cool and dark room, limiting screen time before bed
• Discuss relaxation techniques, cognitive-behavioral therapy for insomnia (CBT-I), regular exercise, and stress management as adjuncts or alternatives to medication

Tapering and discontinuation:

• Patients should never stop benzodiazepines abruptly after prolonged use. Gradual tapering under provider guidance is required to prevent withdrawal symptoms (anxiety rebound, tremors, seizures)
• Educate about rebound insomnia, which can occur when discontinuing certain sleep medications, and reassure patients that this is typically temporary
• Instruct patients to report any concerning symptoms promptly, including signs of withdrawal, worsening anxiety, or unusual sleep behaviors

Follow-up:

• Schedule regular appointments to assess medication effectiveness, monitor for adverse effects, and re-evaluate the ongoing need for the medication
• These drugs are generally intended for short-term use; long-term therapy should be periodically reassessed